- Company
-
- Aifinyo AG
- Aixtron SE
- Berentzen Gruppe AG
- Amadeus Fire AG
- Brain Biotech AG
- Carl Zeiss Meditec AG
- Cherry SE
- Deutz AG
- Edag Engineering Group AG
- ElringKlinger AG
- Encavis AG
- Energiekontor AG
- Gerresheimer AG
- Hypoport SE
- Jost Werke SE
- Knaus Tabbert AG
- LEG Immobilien SE
- Mister Spex SE
- Mountain Alliance AG
- Mutares SE
- Nemetschek SE
- PSI Software SE
- Rational AG
- RENK Group AG
- Schaltbau Holding AG
- SFC Energy AG
- Sixt SE
- Talanx AG
- USU Software AG
- Varta AG
- voxeljet AG
- Verve Group SE
- Wacker Chemie AG
- Zeal Network SE
- Presentations
- Index
- Blog
- About
🇩🇪 Germany · Prime Standard · Industrial Biotech
BRAIN Biotech AG Pioneering the biologization of industry
A leading European specialist in industrial biotechnology developing bio-based products and solutions for nutrition, health, and the environment supporting a more sustainable, circular economy.
BNN
Ticker
Prime Std.
Segment
Biotech
Sector
DE 🇩🇪
HQ
1993
Founded
seat11a · BRAIN Biotech video hub
BRAIN Biotech AG Investor Relations Video Hub
All CEO & CFO video presentations from BRAIN Biotech AG filter by format below to find what you need.
BRAIN Biotech AG
BRAIN Biotech AG Elevator Pitch | Enzymes, Bioeconomy & Innovation
BRAIN Biotech Elevator Pitch with CFO Michael Schneiders. Learn about industrial biotechnology, specialty enzymes, BioIncubator, and the company's Top 10 growth ambition.
Watch presentation
BRAIN Biotech AG Financial Results H1 2025 / 26 | Enzymes, CRISPR, BioIncubator projects, and bioeconomy innovation.
Watch
BRAIN Biotech AG Financial Results FY 2024 / 25 | Monetization, Margins & Enzyme growth initiatives
Watch
BRAIN Biotech AG Deep Dive | AI-Driven Enzyme Discovery, U.S. Expansion, and Growth Strategy Explained
Watch
BRAIN Biotech AG Financial Results 9M 2024 / 25 | Strong Core Growth & BioIncubator Innovations
Watch
BRAIN Biotech AG Elevator Pitch | Strategy & Vision
Watch
BRAIN Biotech AG Financial Results H1 2024 / 25 | Momentum & Strategic Focus
Watch
BRAIN Biotech AG Financial Results Q1 2024 / 25 | Growth, Innovation & Outlook
Watch
BRAIN Biotech AG Financial Results FY 2023 / 24 | Financial Performance and Growth Strategy with CFO
Watch
BRAIN Biotech AG Financial Results 9M 2023 / 24 | Strategic Growth in Challenging Economy with Strong Cash Position
Watch
BRAIN Biotech AG Financial Results H1 2023 / 24 | Robust Results and Strategic Outlook
Watch
BRAIN Biotech AG Elevator Pitch 2025 | Strategie und Visionen (Deutsche Version)
Watch
BRAIN Biotech AG Financial Results Q1 2023 / 24 | Strategic Financial Outlook with CFO
Watch
BRAIN Biotech AG Financial Results 9M 2022 / 23 | Journey to Sustainability & Prosperity with CFO
Watch
BRAIN Biotech AG Financial Results H1 2022 / 23 | Steady Growth, Strategy, and Future Outlook with CFO
Watch
BRAIN Biotech AG Deep Dive 2023 | Revolutionizing the Food & Healthcare Industries with CFO
Watch
BRAIN Biotech AG Financial Results Q1 2022 / 23 | Revenue and Cash Improved with CFO
Watch
BRAIN Biotech AG Financial Results FY 2021 / 22 | Exploring Growth, Challenges, and Future Prospects with CFO
Watch
BRAIN Biotech AG Financial Results 9M 2021/ 22 | Unveiling the Future with IR
Watch
BRAIN Biotech AG ESG | Targets, Opportunities and Key Points with IR
Watch
BRAIN Biotech AG Financial Results H1 2021 / 22 | Highlights, ESG and Mid-Term Targets with IR
Watch
BRAIN Biotech AG Financial Results Q1 2021 / 22 | Unveiling Strategic Deals & Growth Trajectory with IR
Watch
BRAIN Biotech AG Financial Results FY 2020 / 21 | Innovations, and Sustainability Commitments with IR
Watch
BRAIN Biotech AG Deep Dive | Unlocking the Power of Biotechnology with CFO
Watch
BRAIN Biotech AG Company Presentation | Pioneering the Future of Industrial Biotechnology with IR
Watch
BRAIN Biotech AG Elevator Pitch | Transforming Industries with Biotechnology with IR
Watch
BRAIN Biotech AG Deep Dive The CRISPR Cas9 Opportunity with IR
Watch
BioScience
Contract research & innovation incubator
BioIndustrial
Enzymes, microorganisms & bioactives
Bioarchive
Microorganisms, DNA & natural substances
Sustainability
UN Global Compact participant
Headquarters
BRAIN Biotech AG
Darmstaedter Strasse 34-36, 64673 Zwingenberg
Company overview
Driving the biologization of industry for a sustainable economy
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group, headquartered in Zwingenberg, Germany, with production facilities in Germany, the UK and the US.
Two Business Segments: BioScience & BioIndustrial
Two pillars form the BRAIN Group's business. The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. The BioIndustrial segment focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and their respective distribution to customers worldwide.
BRAIN Bioarchive and Technology Portfolio
The BRAIN Group maintains its own diverse collection of natural resources the BRAIN Bioarchive, comprising microorganisms, genetic material and natural substances. Built on this collection and a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in industry. Proprietary production facilities and biotechnological production expertise complete the value chain within the Group.
Commitment to Sustainability and Capital Markets
As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and to taking actions that advance broader societal goals. Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
Want your company
on seat11a?
Join BRAIN Biotech and 100+ listed companies reaching institutional investors through CEO and CFO video presentations.
